2025
Imetelstat in myeloid malignancies: current data and future directions
Bidikian A, Bewersdorf J, Kewan T, Podoltsev N, Stahl M, Zeidan A. Imetelstat in myeloid malignancies: current data and future directions. Expert Review Of Anticancer Therapy 2025, 25: 517-528. PMID: 40116730, DOI: 10.1080/14737140.2025.2482721.Peer-Reviewed Original ResearchMyelodysplastic syndromeLR-MDSClinical trialsPotential disease-modifying propertiesLow-risk myelodysplastic syndromesElevated liver enzymesLR-MDS patientsTreat myelodysplastic syndromeSearch of PubMedTransfusion independenceEssential thrombocythemiaInfusion reactionsMyeloid malignanciesDisease-modifying propertiesCombination therapySurvival benefitEffective telomerase inhibitorImetelstatTelomerase reactivationPatient populationLiver enzymesMyelofibrosisCancer cellsMalignancyConference abstracts
2024
Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia
Jain A, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, Kuykendall A, Chan O, Sweet K, Lancet J, Padron E, Sallman D, Komrokji R. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia. Haematologica 2024, 109: 2157-2164. PMID: 38299605, PMCID: PMC11215361, DOI: 10.3324/haematol.2023.283661.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAcute myeloid leukemia transformationMulti-lineage dysplasiaAbsolute neutrophil countMyelodysplastic syndromeSomatic mutationsLR-MDSMyeloid leukemiaBone marrowLow-risk myelodysplastic syndromesHigh-risk myelodysplastic syndromeLow absolute neutrophil countLow riskHigh riskHigh bone marrowAssociated with less progressionLow platelet countHigh-risk diseaseLR-MDS patientsMDS patientsRinged sideroblastsRisk diseaseSF3B1 mutationsBM fibrosisPlatelet count
2023
Improved Overall Survival Among Luspatercept Responders and Predictors of Response
Consagra A, Lanino L, Al Ali N, Aguirre L, Xie Z, Chan O, Andreossi G, Rigodanza L, Sanna A, Raddi M, Walker A, Kuykendall A, Lancet J, Padron E, Sallman D, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Campagna A, Della Porta M, Santini V, Komrokji R. Improved Overall Survival Among Luspatercept Responders and Predictors of Response. Blood 2023, 142: 1871. DOI: 10.1182/blood-2023-186279.Peer-Reviewed Original ResearchMoffitt Cancer CenterIPSS-MMedian OSRBC-TDRBC-TIErythroid stimulating agentsHematologic responsePredictors of responseOverall survivalNon-respondersHgb increasesTransfusion burdenHypomethylating agentsRinged sideroblastsLR-MDSAdverse eventsFirst-in-class erythroid maturation agentAssociated with improved OSMedian duration of responseLow-risk myelodysplastic syndromesRed blood cell transfusionErythroid maturation agentLow TB groupMedian OS benefitRBC transfusion burden
2021
The Natural History of Lower Risk MDS: Factors Predicting Progression to High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Very Low and Low Risk MDS According to the R-IPSS Criteria
Jain A, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, Kuykendall A, Chan O, Sweet K, Lancet J, Padron E, Sallman D, Komrokji R. The Natural History of Lower Risk MDS: Factors Predicting Progression to High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Very Low and Low Risk MDS According to the R-IPSS Criteria. Blood 2021, 138: 2600. DOI: 10.1182/blood-2021-149708.Peer-Reviewed Original ResearchAcute myeloid leukemia transformationLow-risk myelodysplastic syndromesHigh-risk myelodysplastic syndromeRisk myelodysplastic syndromesAcute myeloid leukemiaEntity's Board of DirectorsProgression to acute myeloid leukemiaMulti-lineage dysplasiaAbsolute neutrophil countMyelodysplastic syndromeHR-MDSLR-MDSDisease progressionMedian OSNatural historyLow riskMyeloid leukemiaBone marrowTreated with hypomethylating agentsInternational Prognostic Scoring SystemLower-risk myelodysplastic syndromesHigh risk of disease progressionRisk of disease progressionLow absolute neutrophil countRisk factorsGender Disparities in Myelodysplastic Syndromes: Phenotype, Genotype, and Outcomes
Tinsley-Vance S, Al Ali N, Ball S, Aguirre L, Jain A, Kaldas D, Chan O, Padron E, Sweet K, Lancet J, Kuykendall A, Sallman D, Komrokji R. Gender Disparities in Myelodysplastic Syndromes: Phenotype, Genotype, and Outcomes. Blood 2021, 138: 1984. DOI: 10.1182/blood-2021-149894.Peer-Reviewed Original ResearchMedian overall survivalEntity's Board of DirectorsAllogeneic hematopoietic stem cell transplantationMyelodysplastic syndromeR-IPSSAdvisory CommitteeOverall survivalResearch fundingLower-risk myelodysplastic syndromesLow-risk myelodysplastic syndromesTherapy-related myelodysplastic syndromeHigher-risk myelodysplastic syndromesResponse to immunosuppressive therapyHematopoietic stem cell transplantationMDS databaseRisk myelodysplastic syndromesStem cell transplantationErythroid stimulating agentsSEER registriesKaplan-Meier methodChi-square testHigher platelet countGender differencesCompare categorical variablesMoffitt Cancer Center
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply